The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Antiplatelet Therapy for Stable Coronary Artery Disease in Atrial Fibrillation Patients Taking an Oral Anticoagulant: A Nationwide Cohort Study
Open accessAbstract
Background—: The optimal long-term antithrombotic treatment of patients with coexisting atrial fibrillation and stable coronary artery disease is unresolved, and commonly, a single antiplatelet agent is added to oral anticoagulation. We investigated the effectiveness and safety of adding antiplatelet therapy to vitamin K antagonist (VKA) in atrial fibrillation patents with stable coronary artery disease. Methods and Results—: Atrial fibrillation patients with stable coronary artery disease (defined as 12 months from an acute coronary event) between 2002 and 2011 were identified. The subsequent risk of cardiovascular events and serious bleeding events (those that required hospitalization) was examined with adjusted Cox regression models according to ongoing antithrombotic therapy. A total of 8700 patients were included (mean age, 74.2 years; 38% women). During a mean follow-up of 3.3 years, crude incidence rates were 7.2, 3.8, and 4.0 events per 100 person-years for myocardial infarction/coronary death, thromboembolism, and serious bleeding, respectively. Relative to VKA monotherapy, the risk of myocardial infarction/coronary death was similar for VKA plus aspirin (hazard ratio, 1.12 [95% confidence interval, 0.94–1.34]) and VKA plus clopidogrel (hazard ratio, 1.53 [95% confidence interval, 0.93–2.52]). The risk of thromboembolism was comparable in all regimens that included VKA, whereas the risk of bleeding increased when aspirin (hazard ratio, 1.50 [95% confidence interval, 1.23–1.82]) or clopidogrel (hazard ratio, 1.84 [95% confidence interval, 1.11–3.06]) was added to VKA. Conclusions—: In atrial fibrillation patients with stable coronary artery disease, the addition of antiplatelet therapy to VKA therapy is not associated with a reduction in risk of recurrent coronary events or thromboembolism, whereas risk of bleeding is increased significantly. The common practice of adding antiplatelet therapy to oral VKA anticoagulation in patients with atrial fibrillation and stable coronary artery disease warrants reassessment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Braunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,487
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · EP Europace · doi:10.1093/europace/eus305 · Cited by 3,822
Self-citationSCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Final Report on the Aspirin Component of the Ongoing Physicians' Health Study
Steering Committee of the Physicians' Health Study Research Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198907203210301 · Cited by 2,264
(2006) · The Lancet · doi:10.1016/s0140-6736(06)68845-4 · Cited by 1,952 · cited 3×
“Proton pump inhibitors 840 (26) 158 (38) 484 (27) 194 (20) 310 (21) 73 (23) 112 (22)”
Dewilde, W. J., Oirbans, T., Verheugt, F. W., Kelder, J. C., De Smet, B. J., Herrman, J.-P., Adriaenssens, T., Vrolix, M., Heestermans, A. A., Vis, M. M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62177-1 · Cited by 1,719
Olesen, J. B., Lip, G. Y. H., Hansen, M. L., Hansen, P. R., Tolstrup, J. S., Lindhardsen, J., Selmer, C., Ahlehoff, O., Olsen, A.-M. S., Gislason, G. H., et al. (2011) · BMJ · doi:10.1136/bmj.d124 · Cited by 1,428
Self-citationMechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited
Watson, T., Shantsila, E., & Lip, G. Y. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60040-4 · Cited by 1,123
Self-citation2012 Writing Committee Members, Jneid, H., Anderson, J. L., Wright, R. S., Adams, C. D., Bridges, C. R., Casey, D. E., Ettinger, S. M., Fesmire, F. M., Ganiats, T. G., et al. (2012) · Circulation · doi:10.1161/cir.0b013e318256f1e0 · Cited by 1,090
Thygesen, L. C., Daasnes, C., Thaulow, I., & Brønnum-Hansen, H. (2011) · Scandinavian Journal of Public Health · doi:10.1177/1403494811399956 · Cited by 1,084
Stroke and bleeding in atrial fibrillation with chronic kidney disease
Olesen, J. B., Lip, G. Y. H., Kamper, A.-L., Hommel, K., Køber, L., Lane, D. A., Lindhardsen, J., Gislason, G. H., & Torp-Pedersen, C. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105594 · Cited by 930
Self-citationAntithrombotic Therapy for Atrial Fibrillation
You, J. J., Singer, D. E., Howard, P. A., Lane, D. A., Eckman, M. H., Fang, M. C., Hylek, E. M., Schulman, S., Go, A. S., Hughes, M., et al. (2012) · Chest · doi:10.1378/chest.11-2304 · Cited by 918
Self-citationHansen, M. L., Sørensen, R., Clausen, M. T., Fog-Petersen, M. L., Raunsø, J., Gadsbøll, N., Gislason, G. H., Folke, F., Andersen, S. S., Schramm, T. K., et al. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.271 · Cited by 855 · cited 3×
“Prednisolone 295 (9) 43 (10) 145 (8) 74 (8) 91 (6) 17 (5) 35 (7)”
Warfarin, Aspirin, or Both after Myocardial Infarction
Hurlen, M., Abdelnoor, M., Smith, P., Erikssen, J., & Arnesen, H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020496 · Cited by 846
Fox, K. A. A., Mehta, S. R., Peters, R., Zhao, F., Lakkis, N., Gersh, B. J., & Yusuf, S. (2004) · Circulation · doi:10.1161/01.cir.0000140675.85342.1b · Cited by 835
Schneeweiss, S. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1200 · Cited by 727
Sørensen, R., Hansen, M. L., Abildstrom, S. Z., Hvelplund, A., Andersson, C., Jørgensen, C., Madsen, J. K., Hansen, P. R., Køber, L., Torp-Pedersen, C., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61751-7 · Cited by 575
Self-citationMadsen, M. (2003) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(02)00591-7 · Cited by 460
Oral Anticoagulant and Antiplatelet Therapy and Peripheral Arterial Disease
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa065959 · Cited by 442
Uchino, K. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.1666 · Cited by 431
Lamberts, M., Olesen, J. B., Ruwald, M. H., Hansen, C. M., Karasoy, D., Kristensen, S. L., Køber, L., Torp-Pedersen, C., Gislason, G. H., & Hansen, M. L. (2012) · Circulation · doi:10.1161/circulationaha.112.114967 · Cited by 413 · cited 5×
“Intermediate (1) 130 (4) 34 (8) 120 (7) 42 (4) 62 (4) 19 (6) 38 (8)”
InfluentialSelf-citationBaigent, C., Collins, R., Appleby, P., Parish, S., Sleight, P., & Peto, R. (1998) · BMJ · doi:10.1136/bmj.316.7141.1337 · Cited by 404
Validity of Stroke Diagnoses in a National Register of Patients
Krarup, L.-H., Boysen, G., Janjua, H., Prescott, E., & Truelsen, T. (2007) · Neuroepidemiology · doi:10.1159/000102143 · Cited by 366
An automated database case definition for serious bleeding related to oral anticoagulant use
Cunningham, A., Stein, C. M., Chung, C. P., Daugherty, J. R., Smalley, W. E., & Ray, W. A. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2109 · Cited by 359
Lamberts, M., Gislason, G. H., Olesen, J. B., Kristensen, S. L., Schjerning Olsen, A.-M., Mikkelsen, A., Christensen, C. B., Lip, G. Y. H., Køber, L., Torp-Pedersen, C., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.029 · Cited by 334
Self-citationBanerjee, A., Lane, D. A., Torp-Pedersen, C., & Lip, G. Y. H. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-11-0784 · Cited by 301
Self-citationExternal Validity of Clinical Trials in Acute Myocardial Infarction
Steg, P. G. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.1.68 · Cited by 269
Mukamal, K. J., Tolstrup, J. S., Friberg, J., Jensen, G., & Grønbæk, M. (2005) · Circulation · doi:10.1161/circulationaha.105.547844 · Cited by 269
Lip, G. Y. H., Huber, K., Andreotti, F., Arnesen, H., Airaksinen, J. K., Cuisset, T., Kirchhof, P., & Marin, F. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq117 · Cited by 229
Self-citationEikelboom, J., Berger, P., Holmes, D., Bhatt, D., Becker, R., Angiolill, D., Faxon, D., & Moliterno, D. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-04-0262 · Cited by 204
Flaker, G. C., Gruber, M., Connolly, S. J., Goldman, S., Chaparro, S., Vahanian, A., Halinen, M. O., Horrow, J., & Halperin, J. L. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.06.024 · Cited by 181
Komócsi, A., Vorobcsuk, A., Kehl, D., & Aradi, D. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.4026 · Cited by 79
Hommel, K., Rasmussen, S., Madsen, M., & Kamper, A. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp571 · Cited by 73
Cited by
2017 ESC/EACTS Guidelines for the management of valvular heart disease
Baumgartner, H., Falk, V., Bax, J. J., De Bonis, M., Hamm, C., Holm, P. J., Iung, B., Lancellotti, P., Lansac, E., Rodriguez Muñoz, D., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx391 · Cited by 6,243
2021 ESC/EACTS Guidelines for the management of valvular heart disease
Vahanian, A., Beyersdorf, F., Praz, F., Milojevic, M., Baldus, S., Bauersachs, J., Capodanno, D., Conradi, L., De Bonis, M., De Paulis, R., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab395 · Cited by 5,685
Valgimigli, M., Bueno, H., Byrne, R. A., Collet, J.-P., Costa, F., Jeppsson, A., Jüni, P., Kastrati, A., Kolh, P., Mauri, L., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx419 · Cited by 2,987
Self-citationVirani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001168 · Cited by 1,598
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.-C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2015) · Europace · doi:10.1093/europace/euv309 · Cited by 1,113
Metadata
- Authors
- Lamberts, M., Gislason, G. H., Lip, G. Y. H., Lassen, J. F., Olesen, J. B., Mikkelsen, A. P., Sørensen, R., Køber, L., Torp-Pedersen, C., & Hansen, M. L.
- Venue
- Circulation
- Published
- 2014-04-15
- Volume
- 129
- Issue
- 15
- Pages
- 1577-1585
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2884532285
- Cited by
- 284
- References
- 36
- FWCI
- 18.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.